三氧化二砷对支气管哮喘免疫及气道炎症的调控

Regulation on immunity and airway inflammation of bronchial asthma by arsenic trioxide

支气管哮喘（简称哮喘）是一种由多种细胞（嗜酸粒细胞、T细胞、中性粒细胞、肥大细胞及肺泡上皮细胞等）及细胞组分参与的气道慢性炎症性疾病。二氧化二砷在动物实验中能改善哮喘小鼠的肺功能，在临床治疗中能使患者的哮喘症状得到长期控制。新近研究表明：三氧化二砷能明显抑制小鼠的体液免疫反应，抑制小鼠的肺、皮肤等组织的T细胞增殖，能下调IL-17、IL-18和IL-23等多种炎症因子的分泌，并且通过内质网应激途径诱导中性粒细胞凋亡，从而调节免疫，抑制炎症。文章综述了三氧化二砷调控哮喘免疫及气道炎症的最新研究进展，并进行了展望。

Bronchial asthma （asthma） is a kind of chronic inflammation of airway, which was involved in many kinds of cells and cellular elements, such as eosinophils, T lymphocytes, neutrophil granulocytes, mastocytes, alveolar epithelial cells, and so on. Arsenic trioxide can improve the asthmatic mice＇s pulmonary function in experiment, and own the ability of hold the patients＇ asthmatic symptoms in a better state for a long time. The recent researchs indicated that the arsenic trioxide can regulate immunity and inhibit airway inflammation through many effective processes, such as inhibiting humoral immunity and proliferation of T lymphocytes at skin and lung, down regulating expression of inflammatory factors （IL-17, IL -18, IL -23,etc）, and inducing apoptosis of neutrophil granulocytes by endoplasmic reticulum stress pathway. The newest studies about the regulation on immunity and airway inflammation of asthma by arsenic trioxide were summarized, and some possible research orientation was previewed.